Brian Daniels - Novo Nordisk Independent Director
| NVO Stock | USD 124.02 5.19 4.02% |
Director
Dr. Brian Daniels, M.D. was Independent Director at Novo Nordisk AS since March 18, 2016. He is Member of the Remuneration and Research Development Committees. He is Venture Partner with 5AM Venture Management, LLC, the United States. He has experience in clinical development, medical affairs and corporate strategy across a broad range of therapeutics areas within the pharmaceutical industry, especially in the US. He holds MD from Washington University, St. Louis, US, BS in Life Sciences and MA in Metabolism and Nutritional Biochemistry, both from Massachusetts Institute of Technology, Cambridge, US. since 2016.
| Age | 61 |
| Tenure | 8 years |
| Professional Marks | Ph.D |
| Address | Novo Alle 1, Bagsvaerd, Denmark, 2880 |
| Phone | 45 44 44 88 88 |
| Web | https://www.novonordisk.com |
Novo Nordisk Management Efficiency
The company has Return on Asset of 0.2339 % which means that on every $100 spent on assets, it made $0.2339 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.8807 %, implying that it generated $0.8807 on every 100 dollars invested. Novo Nordisk's management efficiency ratios could be used to measure how well Novo Nordisk manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Novo Nordisk's Return On Tangible Assets are very stable compared to the past year. As of the 3rd of May 2024, Return On Capital Employed is likely to grow to 0.74, while Return On Assets are likely to drop 0.14. At this time, Novo Nordisk's Return On Tangible Assets are very stable compared to the past year. As of the 3rd of May 2024, Intangibles To Total Assets is likely to grow to 0.20, while Non Currrent Assets Other are likely to drop about 1.4 B.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Alain Schreiber | Eagle Pharmaceuticals | 58 | |
| Richard Edlin | Eagle Pharmaceuticals | 57 | |
| Dennis Walsh | Deciphera Pharmaceuticals LLC | 50 | |
| Steven Ratoff | Eagle Pharmaceuticals | 81 | |
| Robert Glenning | Eagle Pharmaceuticals | 57 | |
| Michael Ross | Deciphera Pharmaceuticals LLC | 68 | |
| Michael Graves | Eagle Pharmaceuticals | 61 | |
| Edward Kay | Eagle Pharmaceuticals | N/A | |
| Patricia Allen | Deciphera Pharmaceuticals LLC | 56 | |
| Liam Ratcliffe | Deciphera Pharmaceuticals LLC | 53 | |
| Sander Flaum | Eagle Pharmaceuticals | 81 | |
| Susan Kelley | Deciphera Pharmaceuticals LLC | 63 | |
| John Martin | Deciphera Pharmaceuticals LLC | 57 | |
| Douglas Braunstein | Eagle Pharmaceuticals | 57 | |
| James Bristol | Deciphera Pharmaceuticals LLC | 71 | |
| Edward Benz | Deciphera Pharmaceuticals LLC | 71 | |
| David Pernock | Eagle Pharmaceuticals | 63 | |
Management Performance
| Return On Equity | 0.88 | ||||
| Return On Asset | 0.23 |
Novo Nordisk AS Leadership Team
Elected by the shareholders, the Novo Nordisk's board of directors comprises two types of representatives: Novo Nordisk inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novo. The board's role is to monitor Novo Nordisk's management team and ensure that shareholders' interests are well served. Novo Nordisk's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novo Nordisk's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Soeren Pedersen, Director, Employee Representative | ||
| Doug Langa, Senior Vice President Head of North America Operations and Presidentident of Novo Nordisk Inc. | ||
| Jakob Riis, Executive VP of China, Pacific and Marketing and Member of Executive Management | ||
| Kasim Kutay, Director | ||
| Jesper Brandgaard, CFO, Executive Vice President | ||
| Sylvie Gregoire, Independent Director | ||
| Mette Jensen, Director, Employee Representative | ||
| Mary Szela, Director | ||
| Jerzy Gruhn, Executive Vice President Europe | ||
| Douglas Langa, Executive Vice President - North America Operations | ||
| Eivind Kolding, Director | ||
| Kasper Poulsen, Head of Investor Relations, Corporate Vice President | ||
| Thomas Rantzau, Director, Employee Representative | ||
| Lars Jorgensen, CEO President | ||
| Daniel Bohsen, CVP Relations | ||
| Henrik Poulsen, Director | ||
| Karsten Knudsen, Chief Financial Officer, Executive Vice President | ||
| Lars Joergensen, President, Chief Executive Officer | ||
| Helge Lund, Independent Chairman of the Board | ||
| Martin Lange, Executive Vice President - Development | ||
| Maziar Doustdar, Executive Vice President - International Operations | ||
| Brian Daniels, Independent Director | ||
| Goran Ando, Chairman of the Board | ||
| Martin Mackay, Independent Director | ||
| Jeppe Christiansen, Vice Chairman of the Board | ||
| Bruno Angelici, Independent Director | ||
| Liselotte Hyveled, Director, Employee Representative | ||
| Anne Kverneland, Director, Employee Representative | ||
| Tania Sabroe, Executive Board | ||
| Kaare Schultz, President COO | ||
| Liz Hewitt, Independent Director | ||
| Jesper Hoeiland, Executive Vice President US | ||
| Ludovic Helfgott, Executive Vice President of Biopharm | ||
| Camilla Sylvest, Executive Vice President - Commercial Strategy and Corporate Affairs | ||
| Mads Thomsen, Chief Science Officer, Executive VP and Member of Executive Management | ||
| Andreas Fibig, Independent Director | ||
| Monique Carter, Executive Vice President - People and Organisation | ||
| Peter Ankersen, Corporate Vice President & Head of Investor Relations | ||
| Laurence Debroux, Independent Director | ||
| Lars Soerensen, CEO | ||
| Marcus Schindler, Executive Vice President - Research and Early Development, Chief Scientific Officer | ||
| Stig Stroebaek, Director, Employee Representative | ||
| Henrik Wulff, Executive Vice President - Product Supply Quality and IT | ||
| Thomas Koestler, Independent Director | ||
| Lars Green, Executive Vice President Business Services & Compliance |
Novo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Novo Nordisk a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.88 | ||||
| Return On Asset | 0.23 | ||||
| Profit Margin | 0.36 % | ||||
| Operating Margin | 0.43 % | ||||
| Current Valuation | 572.83 B | ||||
| Shares Outstanding | 4.46 B | ||||
| Shares Owned By Institutions | 9.31 % | ||||
| Number Of Shares Shorted | 3.24 M | ||||
| Price To Earning | 37.42 X | ||||
| Price To Book | 36.21 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Complementary Tools for Novo Stock analysis
When running Novo Nordisk's price analysis, check to measure Novo Nordisk's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novo Nordisk is operating at the current time. Most of Novo Nordisk's value examination focuses on studying past and present price action to predict the probability of Novo Nordisk's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novo Nordisk's price. Additionally, you may evaluate how the addition of Novo Nordisk to your portfolios can decrease your overall portfolio volatility.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |
Is Novo Nordisk's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novo Nordisk. If investors know Novo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novo Nordisk listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.631 | Dividend Share 9.4 | Earnings Share 2.67 | Revenue Per Share 51.812 | Quarterly Revenue Growth 0.37 |
The market value of Novo Nordisk AS is measured differently than its book value, which is the value of Novo that is recorded on the company's balance sheet. Investors also form their own opinion of Novo Nordisk's value that differs from its market value or its book value, called intrinsic value, which is Novo Nordisk's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novo Nordisk's market value can be influenced by many factors that don't directly affect Novo Nordisk's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novo Nordisk's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novo Nordisk is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novo Nordisk's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.